what is gip and glp-1 receptors Dual GIP/GLP-1 receptor agonists: New advances for treating type-2 diabetes Science Behind GLP 1 GIP

Phase 2 trial data published in 2023 in the New England Journal of Medicine (Jastreboff et al., NEJM 2023) reported mean weight reductions of up to approximately 24% over 48 weeks in adults with obesity notably higher than results seen with currently approved agents

Semaglutide mimics and amplifies this hormone, producing sustained appetite suppression over the course of a week from a single injection

The GLP-1 Weight Loss Revolution: Is It Safe

Rekha Kumar, a practicing endocrinologist in NYC and Chief Medical Officer of Found, told Healthline

PlexusDx supports patients seeking GLP-1 access by offering compounded options at predictable costs and providing genetic context about individual peptide pathway predispositions that may help facilitate more informed conversations with healthcare providers